A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Future oncology (London, England)|2026|Frey C
Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressi…
Review
PMID: 41930781
Journal of primary care & community health|2026|Meilinger A et al.
Emerging research suggests a potential role for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in alcohol use disorder (AUD), because GLP-1 receptors are present in the brain regions involved in dopamine signaling and the human reward system.…
Case Report
PMID: 41914511
Journal of medical economics|2026|Johansson E et al.
PURPOSE: This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increase…
Clinical Trial
PMID: 42012820
Biological psychiatry|2026|McIntyre R
A strategic imperative in mood disorders is to identify innovative mechanisms that translate into improved therapeutics when compared to the extant options. More specifically, there is a need for treatments with greater efficacy, shorter time-to-peak…
Review
PMID: 42069105
Science progress|2026|Gupta A et al.
ObjectiveTo evaluate glucagon-like peptide-1 receptor agonist (GLP-1 RA)-specific associations with hair loss, characterize reported alopecia subtypes and discuss potential underlying mechanisms.MethodsA systematic literature search was conducted acr…
Review
PMID: 41998799
Diabetes, obesity & metabolism|2026|Stupalkowska W et al.
AIM: We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). METHODS: Patients with MASLD and…
PMID: 41969188
Acta neuropsychiatrica|2026|Sioufi M et al.
OBJECTIVE: Impaired autophagy has been implicated in the pathophysiology of neurodegenerative disorders, such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Consistent and replicated evidence indicate that Glucagon-like Peptide-1 Receptor…
Review
PMID: 41684077
The lancet. Diabetes & endocrinology|2026|Pan X et al.|1 citation
The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences. In this Personal View, we critically examine recent advances and identify current and emerging challenge…
Review
PMID: 41389801
Revue medicale suisse|2026|Nanchen G et al.
Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzuma…
PMID: 41540866
Journal of pharmaceutical and biomedical analysis|2026|Alhalabi H et al.
Peptide hormone-based weight-loss therapeutics have gained increasing attention, driven amongst other reasons, by the clinical and commercial success of semaglutide. Their increasing accessibility raises concerns about their potential misuse in sport…
Animal StudyIn Vitro
PMID: 41702251
PLoS medicine|2026|Chrzanowski J et al.
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the management of type 2 diabetes (T2DM). Recent case reports have raised concerns about a potential association between semaglutide use and the development of no…
PMID: 42166479
Diabetes, obesity & metabolism|2026|Engström A et al.
AIMS: To investigate the association between use of GLP-1 receptor agonists and incident Parkinson's disease. MATERIAL AND METHODS: Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active-comparator, new-user des…
PMID: 41994910
BMJ open|2026|Yammine L et al.
INTRODUCTION: Cocaine use disorder (CUD) is a significant public health concern in the USA, with considerable prevalence and mortality and no Food and Drug Administration (FDA)-approved pharmacotherapies. Recent advances in addiction science emphasis…
PMID: 42161545
Renal failure|2026|Wang Y et al.|1 citation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in patients with chronic kidney disease (CKD), but existing evidence regarding their efficacy and safety remains inconsistent. To evaluate the cardiorenal outcomes and adverse effe…
ReviewMeta-Analysis
PMID: 41644273
Obesity pillars|2026|Mondoh A et al.
INTRODUCTION: Obesity is a complex and chronic disease associated with complications including type 2 diabetes, cardiovascular disease, and malignancy. Although pharmacotherapy has emerged as an effective treatment option, the determinants of patient…
PMID: 41815755
Free radical biology & medicine|2026|Paidlewar M et al.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia in elderly people, marked by the accumulation of amyloid-β plaques and neurofibrillary tangles, resulting in neurodegeneration and cognitive declin…
Review
PMID: 41864364
Current pharmaceutical design|2026|Papaetis G, Picolos M
Alcohol use disorder (AUD) is a chronically relapsing disorder characterized by a compulsive alcohol drinking pattern, loss of control over intake, and the emergence of negative emotional states promoting alcohol dependence. It is unquestionably a ma…
PMID: 41937527
Frontiers in endocrinology|2026|Alhazmi A, le Roux C
PMID: 41852477
JAAPA : official journal of the American Academy of Physician Assistants|2026|Niedbala C
Obesity is a complex, multifactorial disease. Rates of obesity are rising worldwide. Bariatric surgery is the most effective treatment for obesity, as it results in the greatest weight loss as well as significant improvement in or resolution of obesi…
Review
PMID: 41733456
Clinical and molecular hepatology|2026|Lee B et al.
PMID: 41644110